Hutchmed (china) announced on November 28, 2024, that Vorasertib® (savatinib) successfully renewed its inclusion in China's national medical insurance drug catalog, effective from January 1, 2025. Vorasertib® is a potent, highly selective oral MET tyrosine kinase inhibitor, conditionally approved for use in China in June 2021 for treating non-small cell lung cancer patients with specific MET exon 14 skipping mutations. This move will help improve the affordability of the drug and continue to support the treatment of lung cancer patients in china.\nVorasertib® was first included in the medical insurance drug catalog on March 1, 2023, maintaining the same terms as the existing two-year agreement in this renewal. The chinese government emphasizes improving the affordability of medications for the public, with 1.33 billion people covered by...Show More

Hutchmed (china) announced on November 28, 2024, that Vorasertib® (savatinib) successfully renewed its inclusion in China's national medical insurance drug catalog, effective from January 1, 2025. Vorasertib® is a potent, highly selective oral MET tyrosine kinase inhibitor, conditionally approved for use in China in June 2021 for treating non-small cell lung cancer patients with specific MET exon 14 skipping mutations. This move will help improve the affordability of the drug and continue to support the treatment of lung cancer patients in china.\nVorasertib® was first included in the medical insurance drug catalog on March 1, 2023, maintaining the same terms as the existing two-year agreement in this renewal. The chinese government emphasizes improving the affordability of medications for the public, with 1.33 billion people covered by basic medical insurance, maintaining a coverage rate of around 95%. The medical insurance drug catalog is adjusted annually, innovative drugs are renewed every two years, and the national medical insurance bureau gathers expert networks for drug updates and adjustments.\nVorasertib® was co-developed by Hutchmed (china) and astrazeneca, with astrazeneca responsible for commercialization. The drug is approved in china for treating non-small cell lung cancer patients with MET exon 14 skipping mutations who have experienced disease progression after systemic treatment or are unable to undergo chemotherapy. Hutchmed (china) is committed to bringing self-discovered anti-tumor candidate drugs to global patients and has obtained approvals in china, usa, europe, and japan.